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REKA BENTUK DAN PENILAIAN SISTEM MULTIP AR.TIKEL YANG 
DISEDIAKAN DENGAN MENGGUNAKAN SFERONISASI TAPISAN DAN 
SFERONISASI EKSTRUSI 
ABSTRAK 
Dosej berbentuk pelet boleh disediakan melalui pelbagai kaedah yang biasanya 
memakan masa serta memerlukan tenaga kerja yang banyak. Kajian ini dijalankan untuk 
menilai kebolehlaksanaan penyediaan pelet bulat melalui tapisan jisim serbuk basah dan 
dikuti dengan proses sferonisasi. Kaedah ini dibandingkan dengan proses sferonisasi 
ekstrusi dari segi ciri-ciri fizikal and profil pelarutan in-vitro daripada rumusan yang 
dibangunkan. Pelet parasetamol pelepasan cepat terdiri daripada selulosa mikrohablur, 
laktos, krosi)Ovidon dan polivinil pirolidon-K90. Penitusan basil pelet parasetamol yang 
terhasil melalui proses sferonisasi tapisan adalah lebih tinggi (p< 0.05) berbanding 
dengan yang terhasil melalui proses sferonisasi ekstrusi. Sebaliknya, sferonisasi ekstrusi 
menunjukkan kebolehaliran yang lebih baik (p<0.05) daripada sferonisasi tapisan. 
Walau bagaimanapun, tiada perbezaan yang signifikan ditemui dalam sifat fizikal yang 
lain bagi kedua-dua kaedah. Profil pelarutan didapati lebih tinggi dalam teknik 
sferonisasi tapisan. Kesamaan faktor menunjukkan bahawa profil pelarutan boleh 
dibandingkan dalam rumusan yang disediakan bagi kedua-dua kaedah dan mengikuti 
kinetik tertib pertama. Kadar pelep1;1san drug tidak bergantung pada pH dan juga kadar 
goncangan. Pelet bulat omeprazol yang mempunyai kadar pelepasan yang dikehendaki 
dibangunkan dengan menggunakan proses sferonisasi tapisan. Pelet yang mempunyai 
ciri-ciri yang dikehendaki diperoleh dengan menggunakan jumlah minimum selulosa 
mikrohablur (16% ), laktos, polivinilpirolidon K30, polietilena glikol 6000 dan natrium 
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lauril sulfat. Pelet yang disediakan melalui proses sferonisasi tapisan menunjukkan 
peratusan hasil yang lebih tinggi secara signifikan berbanding dengan yang disediakan 
melalui proses sferonisasi ekstrusi. Sistem pelepasan tertunda omeprazol dibangunkan 
melalui Kollicoat 30DP, dengan menggunakan sistem semburan bawah lapisan terapung 
(bottom spray fluidized bed). Tahap penyalutan sebanyak 17.5 % dapat menghalang 
pelepasan drug kurang daripada 10% pada pH 1 untuk 2 jam pertama dan pada 
pelepasan pH 6.8 adalah 80 hingga 84% dalam 45 minit, mengikut kinetik pelepasan 
tertib pertama. Dalam kajian kestabilan dipecutkan,_kedua-dua drug mematuhi degradasi 
tertib sifar. Hayat simpanan dijangka untuk parasetamol and omeprazol adalah 24.42 
dan 21.00 bulan masing-masing pada 25°C. Pelet omeprazol bersalut yang disediakan 
melalui sferonisasi tapisan dan drug rujukan (Zimor®-20mg) dinilai untuk kebiosetaraan, 
menggunakan amah dalam reka bentuk bersilang, dan kedua-dua rumusan didapati 
setara. Kesimpulannnya, dosej berbentuk pelet boleh dirumuskan melalui tapisan dan 
diikuti dengan kaedah sferonisasi yang ringkas, mudah, cepat dan lebih ekonomi 
dibandingkan dengan proses sferonisasi ekstrusi. 
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DESIGN AND EVALUATION OF MULTIP ARTICULATE SYSTEMS 
PREPARED USING SIEVING-SPHERONISATION AND EXTRUSION-
SPHERONISATION 
ABSTRACT 
Pelletised dosage forms can be prepared by different methods which, in general, 
are time consuming and labor intensive. The current study was carried out to assess the 
feasibility of preparing spherical pellets by sieving the wet powder mass followed by 
spheronisation. This method was compared with extrusion-spheronisation process in 
terms of physical characteristics and in-vitro dissolution profile of the developed 
fommlations. The fast release paracetamol pellets were comprised of, microcrystalline 
cellulose, Iactose, crosp6vidone and polyvinyl pyrrolidone-K90. The percentage yield of 
paracetamol pellets produced by sieving-spheronisation was- higher (p<0.05) in 
companson with that produced by extrusion-spheronisation. The extrusion-
spheronisation showed better flowability (p<0.05) than sieving-spheronisation. However, 
no significant difference was found in other physical properties of two methods. The 
dissolution profile was slightly higher in sieving-spheronisation technique, the similarity 
factors showed that dissolution profiles can be considered comparable in the 
formulations prepared by two methods and followed first order kinetics. The rate of drug 
release was essentially independent of pH and agitation rate. Omeprazole spherical 
pellets with required release rate were developed using sieving-spheronisation process. 
Pellets with desired characteristics were obtained with minimum amount of 
microcrystalline cellulose (16% ), lactose, polyvinylpyrrolidone K30, polyethylene 
glycol 6000 and sodium lauryl sulfate. Pellets prepared by sieving-spheronisation 
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showed significantly higher (p<0.05) percentage yield as compared to that of extrusion-
spheronisation. Omeprazole delay release system was develope'd by Kollicoat 30DP, 
using bottom spray fluidised bed system. Coating level of 17.5 % prevented the drug 
release less than 10% at pH 1 for initial 2 hours and at pH 6.8 release was 80 to 84% 
within 45 minutes, following the first order release kinetics. In accelerated stability 
studies, both drugs followed the zero order degradation. The estimated shelf life of 
paracetamol and omeprazole was 24.42 and 21.00 months respectively at 25 °C. Coated 
omeprazole pellets prepared by sieving-spheronisation and the reference drug (Zimor® 
20mg) were evaluated for bioequivalence, using rabbits in cross-over design, and both 
formulations were found to be equivalent. 
In conclusion, the pelletised dosage forms can be formulated- through si·eving 
followed by spheronisation method, which is simple, easy, less time consuming and 
economical as compared to extrusion-spheronisation process. 
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CHAPTER! 
GENERAL INTRODUCTION 
1.1 Pelletisation 
Pelletisation is an agglomeration process that converts fine powders or 
granules of bulk drugs and excipients into small, free flowing, spherical units known 
as pellets (Ghebre-Sellassie and Knoch, 2002; Sawicki and Lunio, 2005). The size 
range of pellets is usually from 0.50 to 1.50 mm. However, other sizes could also be ', 
prepared, depending on the processing technologies employed (Kristensen and 
Schaefar, 1987; Ghebre-Sellassie, 1989). 
1.!.1 Historical review of pelletisation 
The concept of multiple-unit formulations for controlled release applications 
was introduced in the early 1949. Pellets-based extended release products initially 
employed in the form of pills produced by traditional pill making machine. The 
process of pelletisation was revived in early 1950s as a result of the introduction and 
launch of a controlled release product known as spansule capsule by Smith Kline and 
French (SKF) which was an overwhelming success. This was the beginning of the 
age of oral controlled drug delivery system (Ghebre-Sellassie, 1989). Pills of 
different release profiles were combined in predetermined portions and encapsulated 
into hard gelatin capsules to produce sustained-release oral dosage forms. However, 
the number of pills that could be filled into a single capsule was limityd and the 
duration of release could not be extended beyond a few hours. The manufacturing 
process of the pills was difficult, labor-intensive and required experienced personnel. 
This problem was solved to some extent as the processing equipments got more 
sophisticated and tableting machines were capable to produce thousands of tablets 
1 
within minutes. However, in spite of the advancements in reducing processing time 
and perfecting the technology that led to the production of mini tablets suitable for 
• 
encapsulation, the approach did not alleviate the size limitation encountered during 
the development of pills-based sustained release products. However, in 1951, a 
report on the manufacturing process of seeds revolutionised the production of 
pelletised products (Cimicata, 1951 ). The process utilised the standard coating pans 
and involved successive layering of powder and binder on sugar granules until 
spherical seeds of desired size were obtained. Although the process was complicated 
and required days to be completed, it spearheaded a new era and provided the basis 
for development of future pelletisation methods. The pelletisation technology was 
refined and perfected by SKF and was applied to a number of its products (Blyth, 
-
1956; Rees eta/., 1960; Heiml~ch and MacDonnell, 1964). 
In 1964, a new pelletisation technique called spray-congealing process that 
provided sustained-release pellets ranging in size between 0.25 to 2.00 mm was 
patented by SKF (Lauts and Robinson, 1964). At the same time, the marumeriser 
was introduced commercially. The marumeriser and variations of it were 
subsequently patented in the United States (Nakahara, 1966; Moriya, 1971). 
Basically the process involved extrusion of a wet mass of a mixture of active 
ingredients and excipients to produce cylindrical extrudates followed by 
spheronisation of the extrudates in the spheroniser o:r marumeriser. The 
pharmaceutical application of this process for the development of pellets was first 
published in early 1970s (Conine and Hadley, 1970; Woodruff and Nussle, 1972; 
Mailnowski, and Smith, 1975). 
~. 
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As the drug delivery systems became more refined, the role of pellets in 
dosage forms design and development increased. Now pellets are expected to 
continue to play a major role in the design and fabrication of solid dosage forms. 
1.1.2 Advantages of pellets 
In the last two decades, pellets have established their position due to several 
added advantages over single unit dosage forms (Bechgaard and Nielsen, 1978; 
Hellen et al., 1993). Pelletised products not only offer flexibility in dosage form 
design and development but also utilised to improve the drug safety and efficacy 
(Ghebre-Sellasssie, 1989). These multiple unit dosage form can be formulated in the 
form of capsules, tablets and suspensions (Conine and Hadlay, 1970; Jalal et al., 
-
1972; Mailnowski and Smith, ,1975; Bechgaard, 1982; Bechard and Leroux, 1992). 
They disperse freelyl.n the gastrointestinal tract, maximise drug absorption, decrease 
local irritation in gastrointestinal tract caused by single unit dosage form and 
minimise chances of dose dumping without appreciably lowering drug bioavailability 
(Wilson and Washington, 1989; Tang et al., 2005). Pelletised dosage forms also 
reduce variations in gastric emptying and overall transit time (Digenis, 1994). Pellets 
composed of different drug entities can be blended and formulated into a single 
dosage form. This allows the combined delivery of two or more bioactive agents 
which may or may not be chemically compatible, to the same site or to different sites 
within the gastrointestinal tract. In addition the pellets with different release rates of 
the same drug can be combined in a single dosage form (Ghebre Sellasssie, 1989; 
Wan and Lai, 1991). 
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Successful film coating can be applied onto the pellets due to their ideal 
spherical shape and a low surface area-to-volume ratio especially for sustained 
release and acid resistant formulations (Rowe, 1985; Chamblis~, 1992; Vertommen 
et al., 1997). As pellets flow and pack freely with narrow particle size distribution, it 
is not difficult to obtain uniform and reproducible fill weights in tablets and capsules 
(Reynolds, 1970). Pellets, therefore, offer the possibility of achieving a more reliable 
source of drug and facilitating a lower dosage frequency (Bechgaard and Lodefoged, 
1978). Additionally the pellets can be given to patients on nasogastric tube feeding 
who have the problem of swallowing tablets or capsules. 
1.2 Manufacturing considerations of pelletisation 
-
Pellets, according to V~ppala et al. (1997) should be spherical with a smooth 
sui-face (for subsequent film coating), narrow particle size range and contain the 
required ingredients within reasonable size limits. There are certain manufacturing 
constrictions that must be taken into account before the pelletisation process. 
Production of pellets generally involves an expensive process due to highly 
specialised equipments (Ghebre-Sellasssie, 1989; Noche et al., 1994). Processing of 
a single batch may sometimes require a great deal of time to be completed resulting 
in a higher cost of production. Conversely, a short processing time mandates 
utilisation of efficient and unique equipments that require the allocation of 
substantial capital investment. Extruders, spheroniser and rotor granulators fall under 
this category. Formulation variables should be manipulated to accommqdate the 
availability of the equipment and cost effectiveness of the pelletisation process. 
Another processing step that extremely impacts on the successful development of 
pelletisation product is coating of the drug pellets. Although the pellets could 
4 
conceivably be coated in any tablet coating machine, they generally reqmre 
specialised coating equipment for optimum processing, whether the intention of the 
-· coating is for esthetics, identification or controlled release purposes. Therefore, 
accessibility to the relevant coating equipment should be assessed before a decision 
is made to develop pelletised products. The performance of the coated product is 
dictated by the surface morphology, shape, and composition of the core pellets. Drug 
pellets that possess optimum surface properties must be selected for coating , 
(Woodruff and Nuessle, 1972; Ghebre-Sellassie, 1989). 
Segregation is another factor that is important for the successful pelletisation 
process. Segregation occurs whenever a homogenous blend of pellets is subjected to 
- -
any kind of vibration. It is indvced by differences in size or density of pellets. Other 
factors that lead to segregation-are static charges and surface morphology which may 
be generated during the blending process as a result of interparticulate friction 
(Ghebre-Sellassie, 1989). Another important variable, which affects the success of 
the pelletisation method, is the drug content of individual pellet. If the drug content 
of pellet is very high, it is extremely difficult to maintain content uniformity in the 
final dosage form, especially in case of potent drugs (Woodruff and Nuessle, 1972; 
Ghebre-Sellasssie, 1989). 
Loss of a few pellets during the encapsulation process may lead to a 
significant loss in potency. Therefore it is imperative that pellets containing potent 
drugs should contain extremely low quantities of active drug and mixed with the bulk 
of inert excipients (Vuppala et al., 1997; Ghebre-Sellassie, 1989). 
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1.3 Pelletisation methods 
Pellets are currently a popular dosage form for oral application. They can be 
• prepared by several pelletisation techniques (Haring et a!., 2008). Comprehensive 
research has been focused on the improvement and optimization of the existing 
pelletisation skills as well as on the development of novel manufacturing approaches 
that use innovative formulations and processing equipments (Woodruff and Nuessle, 
1972; Noche et al., 1994). 
The most commonly used pelletisation methods are layering and extrusion-
spheronisation. Other pelletisation methods include spherical agglomeration or 
agitation or balling, compression, droplet formation, cryopelletisation and melt 
- -
pelletisation (Ghbere-Sellasie and Knoch, 2002). 
1.3.1 Layering 
In layering process, inert nonpareil or preformed drug nuclei are used for the 
deposition of successive layers of drug in solution, suspension or dry powder. The 
layering process can be further divided into solution or suspension layering and 
powder layering. In solution or suspension layering, the drug particles are either 
dissolved or suspended in binder solution to be sprayed onto the inert material or 
granules of the same drug. During the spraying and drying stage, liquid bridges that 
are convertible to solid bridges, are formed and the process is continued until the 
desired pellet size is achieved (Garnlen, 1985; Chambliss; 1992 and Vuppala et al., 
1997). 
On the other hand powder layering is a growth mechanism that involves the 
6 
deposition of successive layers of dry powder of drug or excipients or both on the 
preformed nuclei with the help of binding solution. These nuclei, while they tumble 
in the rotating pan take the powder drug and form small particles adhered to each 
other and to nuclei due to the development of capillary forces of binding solution 
(Sherrington, 1969; Ghebre-Sellassie et al., 1985; Ghebre-Sellassie and Knoch, 
2002). 
L3.2 Extrusion-spheronisation 
The pelletisation process has improved significantly after the introduction of 
the extruders and spheronisation (Hicks and Freese, 1989; Varshosas et al., 1997, 
Fekete et al., 1998; Basit et al., 1999). It was invented in 1964 by Nakahara and 
introduced for the first time into the pharmaceutical industry by Rynold as well as 
I 
Conine and Hadley. (1970). The process is lengthy and consists of five unit 
operations: (a) dry mixing, (b) preparation of wet mass, (c) extrusion or shaping of 
the wet mass into cylinders, (d) rounding (spheronisation) of particles in to spheres 
and (e) drying (Otsuka et al., 1994). These phases are strongly related to each other 
and the quality ofthe fmal product (Newton, 1994). 
Different types of extruders are available to prepare the extrudates of the wet 
mass. The selection of an extruder depends upon the characteristics of the extrudates 
and the nature of further processing steps required. The five main types of extruders 
commonly used are screw feed extruder, (Reynolds, 1970; Rowe, 1985), sieve 
extruders, basket extruders, roll extruders and ram extruders (Lindberg, 1988; Hicks 
and Freese, 1989; Ghebre-Sellassie and Knoch, 2002; Keleb et al., 2002). 
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Beside the types of extruder, other factors affecting the extrusion process 
include extrusion screen, speed, and temperature. The effect of extrusion screen on 
. 
the pellet and extrudates quality is characterised by two parameters, thickness and 
diameter of perforations. Changing one of these two parameters influences the 
quality of extrudates and of pellets Baert et al. (1993). The extrusion speed is 
important because the total output should be as high as possible for economical 
reasons but several authors reported that increase in the extrusion speed influenced 
the final pellet quality (Goodhart et al., 1973; Pinto et al., 1993). Harrison et al. 
(1985) showed that the surface impairments such as roughness and shark skinning 
became more pronounced with increasing extrusion speed. These surface defects of 
the extrudates lead to pellets of poor quality due to uneven breaking up of extrudates 
-
during the initial stages of sph7ronisation process, resulting in wide range of particle 
size distribution. 
The extruder screen is also important to affect the final quality of pellet. The 
screen is characterised by two parameters, the thickness of the screen and diameter of 
the perforations. Changing one of these two parameters influences the quality of the 
extrudates and pellets. (Malinowski and Smith, 1975; Harrison et al., 1987; Chariot 
eta!., 1987; Hellen eta!., 1993; Hileman eta/., 1993). 
The control of the extrusion temperature is an imperative feature not only 
when a thermolabile drug is processed but also in view of the moisture content. A 
rise in temperature during the extrusion cycle could dramatically alter the moisture 
content of the extrudates due to evaporation of the granulation liquid. This could lead 
to a difference in the quality of the extrudates produced at the beginning of a batch 
8 
and at the end of a batch (Fielden et al., 1988). To avoid a rise in temperature during 
extrusion, the use of screw extruder with a cooling jacket around the barrel to keep 
.. 
the temperature of the given formulation between predetermined limits has been 
reported (Klenebudde and Linder, 1993). 
A spheroniser is a device consisting of a grooved horizontal plate rotated with 
a stationary vertical hollow cylinder fitted with a door to allow the prepared 
spheronizer products. The plate has grooved surface to increase the friction force. 
Generally the diameter of the grooves is 1.5-2.0 times of the target pellet diameter. 
The diameter of the friction plate is approximately 20 em for laboratory scale 
spheroniser and up to 1.0 m for production scale units (Ghebre-Sellassie and Knoch, 
- -
2002). In the spheronisation process the prepared extrudates are loaded on to the 
rotation plate of spheroniser and -are trans:ferred by tlie centrifugal force to the 
periphery of the spheroniser. 
Extrudates during spheronisation process undergo through different stages to 
form round pellets. Initially they form cylinders with round, edges, then dumbbells 
followed by elliptical particles and eventually perfect spheres (Rowe, 1985). Another 
pellet-forming mechanism was suggested by Baert and Remon. (1993) in which the 
initial cylindrical particles are deformed into a bent rope-shaped particle and then 
form a dumbbell and with the twisting action the dumbbell shape breaks into two 
spherical particles with a flat side having a hollow cavity. Eventually, the continued 
action in the spheroniser causes the particles to round off into spheres. 
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Pellet quality is dependent on spheroniser load, speed and time. Spheroniser 
load mainly affects the particle size distribution and the bulk and tap density of the 
final pellets (Vervaet et al., 1995). The yield of pellets in a 'specific size range 
decreases with an increase in the spheroniser speed and at low spheroniser load and 
increase with extended spheronisation time at a higher spheroniser load (Newton et 
al., 1994 ). Barrau et al (1993) found that increasing spheroniser load led to a 
reduction in the roundness but enhancement in the hardness of pellets and the yield 
in the specific size range remained unchanged. Increasing the spheroniser load 
caused an increase in bulk and tap densities but a decrease in the size of pellets 
(Hellen et al., 1993). The spheronisation speed affects the particle size, (Gandhi et al., 
1999) hardness, friability (Bataille et al., 1993 ), roundness, porosity (Bianchini et al., 
1992), bulk and tap densities (Hellen et al., 1993), flowability and surface 
morphology ofpellets (Malinowski and Smith, 1975). 
The spheronisation process can take from 5 to 30 minutes, depending on 
different variables such as elasticity, plasticity, brittleness of material, plate speed, 
plate geometry, load and water content. Spheronisation time mainly affects the 
particle size distribution (Newton et al., 1994), bulk and tap densities of pellets 
(Malinowski and Smith, 1975; Fielden et al., 1992; Hasznos et al., 1992; Hellen et 
al., 1993). 
Pellets can be dried at room temperature (Hasznos et al., 1992) or at elevated 
temperature in a fluidized bed dryer (Fielden et al., 1992; Newton et al., 1994; Baert 
and Remon, 1993; Yuen et al., 1993), microwave or ordinary oven (Bataille et al., 
1993; Govender and Dangor, 1997). Pellet quality is dependent on the type of the 
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drier used. Oven drying provides less porous and harder pellets with a more 
homogenous surface than those dried in the microwave oven (Bataille et al., 1993). 
Studies on the pellets dried by tray drier and fluidized bed cfryer raveled that the 
nature of drying has quantifiable effect on the dramatic crushing strength, elasticity, 
drug release and a qualitative effect on the surface characteristics of pellets (Dyer et 
al., 1994). 
To prepare the wet mass for the extrusion-spheronisation process, different 
types of granulators are available. It is investigated that a great influence of 
granulation step on extrusion-spheronisation process on the pellets hardness and 
disintegration properties (Granderton and Hunter, 1971; Jalal et al., 1972; Ghorab 
. . -
and Adeyeye, 2007). The most commonly used granulator is the planetary mixer 
(Herman et al., 1988; Harrison et al., 1985}. However, in many cases the use of 
higher shear mixer, sigma blade mixer (Elbers et al., 1992; Ku et al., 1993) and a 
continuous granulator have also been reported (Hellen et al., 1993). Nevertheless high 
shear mixers introduce a large amount of heat that may cause evaporation of the 
granulating liquid, therefore influencing the extrusion behav:ior of the- wet mass. It 
can be avoided by cooling the granulation bowl (Pinto et al., 1993). 
1.3.3 Spherical agglomerations (agitation or balling) 
Balling or agglomeration process has little application m pharmaceutical 
industry but has greater role in the ore and fertilizer industries. In balling, the finely 
divided particles are converted to pellets with the addition of appropriate quantities 
of liquid prior to or during their continuous rolling in drums, discs or mixers (Bhrany 
et al., 1962; Sastry and Fuerstenau, 1971; Ghebre-Sellassie and Knoch, 2002). It can 
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be divided in to two categories, liquid induced agglomeration and melt-induced 
agglomeration. In liquid induced agglomeration, liquid is added to the powder before 
• 
or during the agitation step. As powders come in contact with the liquid phase, they 
form agglomerates or nuclei, which initially are bound together by liquid bridges 
which, on drying, are replaced by solid bridges. The formed nuclei collide with other 
nuclei and coalesce to form larger nuclei or pellets. The coalescence process 
continues until the bonding forces are overcome by breaking forces. At this junction, 
coalescence is replaced by layering, where the small particles are adhered to the large 
particles and the size is increased until pelletisation process is completed (Wan and 
Jeyabalan 1985). 
- -
Melt-induced agglomeration is similar to the liquid-induced agglomeration 
except that the binding material is melted in the- former -ca:se. In melt-induced -
agglomeration, the pellets are formed with the help of congealed material without 
going through the formation of solvent-based liquid bridges (Schaefer eta/., 1990). 
The limitation of this technique is a wide particle size distribution due to the random 
nature ofthe formation ofthe nuclei (Chambliss, 1992; K.leinebudde, 1997). 
1.3.4 Globulation (droplet formation) 
Another process for the preparation of pellets is globulation in which hot melt 
solutions or suspensions are atomized and through evaporation, cooling or 
solidification pellets are generated (Sherrington and Oliver, 1981). This process can 
be subdivided into two relevant processes, spray drying and spray congealing 
(Ghebre-Sellassie and Knoch, 2002). During spray drying, the drug entities in 
solution or suspension forms are sprayed, with or without excipients into a hot-air 
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stream to generate highly spherical particles. This method is generally applied to 
improve the dissolution rate and bioavailability of poorly soluble drugs. In spray 
congealing method, drug is allowed to melt or dissolve in hot Waxes or fatty acids. 
The hot mixture is then sprayed into an air chamber where the temperature is below 
the melting points of the formulation components to produce spherical congealed 
pellets (Ghebre-Sellassie and Knoch, 2002). 
1.3.5 Compression 
In pelletisation using the compaction process, the mixtures or blends of active 
ingredients and excipients are compacted under pressure to generate pellets of 
defined shape and size. In fact the pellets prepared are small tablets that are spherical 
in shape and easy to fill in capsules. The formulation and proce-ssing variables for the 
pellet production are similar to those employed in the manufacture· of- tablets 
(Ghebre-Sellasie, 1989). 
1.3.6 Cryopelletisation 
Cryopelletisation is a new freezing technique for conversion of aqueous 
solutions or suspensions into solid bead like particles by employing liquid nitrogen 
as the cooling medium (Ghebre-Sellasie and Knoch, 2002). This technique, first 
developed for the nutrition industry as well as for the lyophilization of viscous 
bacterial suspensions, can be used to produce drug loaded pellets in liquid nitrogen at 
160°C. The amount of liquid nitrogen required depends on the solid content and 
temperature of solution or suspension. The pellets are then dried in conventional 
freeze dryers (Knoch, 1994). 
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The equipment used for cryopelletisation consists of a container fitted with 
perforated plates at the bottom. Below the plates at a predetermined distance, there is 
a reservoir of liquid nitrogen in which a conveyor belt with' transport baffles is 
immersed. The perforated plates generate droplets that fall and freeze immediately as 
they come in contact with the liquid nitrogen. The frozen pellets are transported out 
of the nitrogen bath into a storage container at -60°C before drying (Knoch, 1994). 
The most critical step in cryopelletisation is droplet formation, which is 
influenced not only by formulations related variables such as viscosity, surface 
tension and solid content. Solutions or suspensions suitable for cryopelletisation are 
those with high solid contents and low viscosities. 
Another important property is the surface tension of the liquid formulation, -
which partly determines the pellet size. The addition of a surfactant to the 
formulation reduces the surface tension resulting in smaller particles (Knoch, 1994). 
1.3.7 Melt pelletisation 
Melt pelletisation is a process whereby a drug substance and excipients are 
converted into a molten or semi-molten state and subsequently shaped using 
appropriate equipment to provide solid spheres or pellets (Ghebre-Sellasie and 
Knoch, 2002). The process requires several pieces of equipment such as cutters, 
blenders, extruder and spheroniser. The drug substance is first blended with the 
appropriate pharmaceutical excipients, such as polymers and waxes and extruded at a 
predetermined temperature. The extrusion temperature must be high enough to melt 
at least one or more of the formulation components. The extrudates are cut into 
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uniform cylindrical segments. The segments are spheronised in a jacketed 
spheroniser to generate uniform size pellets. The spheronisation temperature needs to 
-· be high to partially soften the extrudates and facilitate deformation and eventual 
spheronisation (Ghbere-Sellasie eta!., 1993). The pellets produced are unique in that 
they are monosize, a property which is unmatched by any other pelletisation 
technique. The melt pelletisation technique in high shear mixer is a viable method to 
develop a sustained-release device (Grassi, 2003). However, the process is still in the , 
developmental stage and additional work is needed before the process becomes a 
routinely used pelletisation technique. 
1.3.8 Sieving-spheronisation process 
- - -
In the present study the method adopted for the formulation of multiple unit 
dosage form was the sieving of wet mass followed by spheronisation. In this process -
various excipients can be used and formulation can be easily modified to suit a wide 
range of drug delivery applications. This process is simple, easy and in addition it is 
a continuous process and within a day several batches can be prepared with 
minimum wastage as compared to extrusion-spheronisation process. 
1.4 Excipients of pellets 
The selection of appropriate excipients is very important in the pelletisation. 
Drugs generally do not possess many of the required properties for the fabrication of 
dosage forms. Excipients are added to pharmaceutical dosage forms mainly to 
produce satisfactory delivery of the drug to the intended site, to impart favorable 
characteristics to the dosage fotm and to facilitate the manufacturing process. Using 
appropriate excipients, the extrusion mixture is formulated to produce a cohesive 
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plastic mass, which remains homogeneous during the process. It must maintain the 
flow during manufacturing and self-lubricating properties as it passes through the die. 
,. 
The resultant extrudates must remain non-adhesive to itself and retain a degree of 
rigidity so that the shape imposed by the die is retained (Conine and Hadley, 1970). 
The excipients used in pellets dosage forms are the same as those in tablet or 
capsule formulations (Harris and Ghebre-Sellassie, 1989). The excipients that may . 
be included in pellet formulations are soluble or insoluble fillers (Vecchio et a!., 
1994 ), pH adjusters, spheronisation enhancers, binders, disintegrants and surfactants 
(Bianchini, 1992). 
Fillers are added in the pellet formulation to increase their bulk and to 
facilitate pellet formation. The commonly used fillers in pelletisation -are 
microcrystalline cellulose (MCC), lactose and starch. In addition they are also 
incorporated in pellet formulation if bulk density of the drug is low, dicalcium 
phosphate or calcium sulphate could be included to adjust the density of the resulting 
pellets. 
Microcrystalline cellulose is used extensively as the principal excipient in the 
production of pellets by extrusion-spheronisation (Reynolds, 1970). It acts as filler, 
diluent, extrusion aid, spheronising enhancer (Fielden and Newton, 1992) and binder 
(Reier and Shangraw, 1966; Malinowski and Smith, 1975). It functions as a 
molecular sponge to absorb water and aids in the binding and lubrication of 
moistened powder mass during extrusion (Fielden et al., 1988; Heng and Koo, 2001). 
It modifies the rheological properties of other ingredients in the mixture. It controls 
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the movement of water through the plastic mass and prevents phase separation when 
it is forced through the apertures during extrusion or subjected to centrifugal forces 
• during spheronisation. Microcrystalline cellulose can be used with or without 
additional binding agents (Sienkiewics et al., 1997). It has the property to be easily 
granulated with water to exhibit the elasticity required for extrusion-spheronisation 
(Miyake et al., 1973 a, b) and yields fairly soft free flowing granules and hard tablets 
that possess usually short disintegration time (Fox et al., 1963). 
Lactose is another commonly used excipient (Rowe, 1985; Vervaet et al., 
1995). It is a widely used binder (Van Kemp et al., 1986), diluent and filler (Harris 
and Ghebre-Sellassie, 1989b ). It is also reported that lactose combined with 
- - - -
microcrystalline cellulose exhibits the elasticity required for extrusion-spheronisation 
in the presence of water (Keleb et al., 2002). 
Binders play an important role in wet-granulation and drug-layering 
processes, affecting the physical, mechanical and release properties of the final 
product (Kokubo and Sumada 1996). Suitable binders are ,starch, gelatin, acacia, 
alginic acid, polyvinylpyrrolidone, carbomer, dextrin, guar gum, hydrogenated 
vegetable oil, glucose syrup, magnes1um aluminum silicate, maltodextrin, 
' polymethacrylates, zein, hydroxypropyl cellulose, hydroxypropyl methylcellulose 
t 
and polyvinylpyrrolidone are the preferred binders. 
Disintegrants are widely used during compaction and spheronisation when 
significant pressure is applied and the resulting pellets are dense. The disintegrants 
employed must be efficient in order to counteract both the effect of the binder and 
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the force of compresswn if the dosage form is intended to release the drug 
immediately. The high water absorptive properties of disintegrants may sometimes 
have a deleterious effect on pellets and should not be overlooked' during formulation 
development. Pellets composed of moisture sensitive drugs could absorb moisture 
upon storage and cause instability of the product (Harris and Ghebre-Sellassie, 1989). 
In pellet formulation the pH adjusters sometimes play an important role. 
Generally, acid labile compounds are protected from the acidic regwns of the 
gastrointestinal tract through the application of an enteric film coat. Buffers may also 
be added to the core formulations to maintain the pH of the core in a favorable range 
for drug stability and to enhance dissolution rate of drug. 
Spheronisation enhancers are used to facilitate the production of spheri-cal 
pellets. These substances confer plasticity on the formulation and also impart binding 
strength and integrity. The extensively used spheronisation enhancers for spherical 
pellets are microcrystalline cellulose, polyvinylpyrrolidone and sodium lauryl 
sulphate (Kristensen, et al., 1987). In addition crospovidone can also be used as a 
spheronisation aid to produce good spherical pellets without the need of a binder 
(Liew et al., 2005). 
The most commonly used granulating liquid is water, although in some cases 
the use of alcohol and water mixture in a ratio of 5:95 has also been reported (Milli 
and Schwarts, 1990). Water plays a vital role in pelletisation process. It acts as a 
binder, during wet mass preparation, a lubricant during extrusion and a plasticiser 
during spheronisation process (Hileman et al., 1993; Wan et al., 1993; Vervaet et al., 
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1995; Heng et a!., 1996; Schmidt and Klenebudde, 1999). The use of different 
amounts of water as a granulating liquid alone or in combination with alcohol affects 
·' the hardness and particle size distribution of the final pellets. The amount and 
distribution of water during extrusion are critical for the success of the 
spheronisation process (Fielden eta!., 1993; Vervaet eta!., 1995). An increase in 
water content was found to cause an increase in pellet size and decrease in porosity, 
friability, dissolution, compressibility, and 'increase in density. The physical . 
properties of the pellets changed significantly as the ratio of the fluids was varied 
(Beart and Remon 1993; Vertommen eta!., 1997; Umprayn et al., 1999; Korakianiti 
eta!., 2000). 
1.5 Characterisation of pellets 
Satisfactory physical properties are important for the --successful pellet 
production. Pellets should be characterised by pellet yield (%) particle s1ze, 
flowability, friability density. and hardness. 
1.5.1 Pellet yield (%) 
The percentage yield is an important factor in pelletisation process. It shows 
the amount of pellets achieved from the wet mass after the pelletisation process. It 
can be determined mathematically using the following equation, (Eq), 
Yield%= Weight of pellets x 100 
Weight of powderingrediens fed initially 
Eq 1.1 
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1.5.2 Particle size analysis 
The size of the pellets can be determined using various parameters, particle 
size distribution, mean diameter, geometric mean diameter, interquartile range, mean 
particle size width and length (Woodruff and Nuessle, 1972; Goodhart eta!., 1973; 
Malinowski and Smith, 1975; O'Connor and Schwarts, 1985; Milli and Schwarts, 
1990; Wan et al., 1993 ). Particle size analysis is in most cases carried out by a simple 
sieve analysis (Fekete et al., 1998; Thoma and Siegler, 1998; Basit et al., 1999; 
Korakianiti et al., 2000; Anderson et al., 2000; Larsen et al., 2003; Chatchawalsaisin 
eta!., 2005). This method is easy, inexpensive and rapid. Some authors reported a 
more advanced method, computer aided image analysis in determining pellet size 
(Fielden et al., 1992; Hellen et al., 1993). 
1.5.3 Friability 
It is necessary to attain acceptable friability of pellets to withstand handling, 
shipping, storage and coating. Pellets are placed and rotated in a friabilator for the 
predetermined time period at a specific rotation speed. The difference in pellet 
weight before and after the rotation is used to calculate the friability. The weight loss 
measured was then used to indicate its friability (Millili and Schwarets, 1990; Basit 
et al., 1999). 
1.5.4 Density 
The bulk and tap densities of pellets are determined to gain an. idea of 
homogeneity of particle size distribution (O'Connor and Schwarts, 1989; Bianchini 
et al., 1992; Baert and Remon, 1993). They also indicate the extent of densification 
of pellets and not influenced by the diameter of pellets. Small size pellets have the 
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higher bulk densities because of smaller inter particle porosities (Thoma and Siegler, 
1998). The true density could be measured by using a pycnometer (Sienkiewics et al., 
1997). While the bulk density of pellets could be calculated using a tap density tester 
and expressed in g/ml by determining the volume of pellets with a known weight in a 
100 milliliter (ml) measuring cylinder, (Varshosas et al., 1997 and Umprayn et al., 
1999). It can also be determined with a powder tester (Ando et al., 2007). 
1.5.5 Flowability test 
Flowability is the free flowing property of the pellets (Bataille et al., 1993; 
Hellen et al., 1993 ). The extent of inter-particle force is employed as an index of flow. 
Adequate flowability is essential to maintain a homogenous capsule filling and 
uniform tablet and capsule weig?t. A number of methods have been reported to assess 
the flowability of pellets. These include, percent compressibility index, vibrating 
spatula, hopper flow, avalanching method (Taylor et al., 2000), critical orifice 
diameter and angle of repose (Sienkiewics et al., 1997). Among all these methods the 
more commonly used are angle of repose and critical orifice diameter. Critical orifice 
diameter involves the use of a cylinder with a series of interchangeable base plate disc 
having orifices with different diameters. To calculate the angle of repose the pellets 
are poured carefully through the funnel until the apex of the conical pile just touches 
the tip of the funnel. (Umprayn et al., 1999). The flowability can also be measured by 
a powder tester (Souto et al., 2005; Ando et al., 2007). 
1.5.6 Hardness 
The hardness of pellets can be correlated with the friability (Reynolds, 1970) 
or can be measured directly (Bataille et al., 1993; Sousa et al., 1996). Otherwise it is 
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measured as the force required to break the pellet of well-known diameter using a 
diametrical crushing force of a tablet strength tester (Sousa et al., 1996; Lundquist et 
al., 1997). It can be measured as the water required to crush a pellet, where a light 
plastic container was placed on the pellet and a load was applied by allowing a 
constant rate of flow of water into the container (Wan and Jeyabalan, 1985). The 
more advanced technique to measure the hardness of pellets is using texture analyser 
(Schmidt and Kleinebudde, 1999; Steckle and Mindermann, 2004). 
1.6 In-vitro evaluation 
The oral route remains the preferred route of drug administration due to its 
convenience, good patient compliance and low medicine production costs. After oral 
administration a drug must be absorbed into the systemic circulation and dissolved in 
I 
·the gastric fluids. Dissolution is an official test used by pharmacopeias to quantify 
the amount and extent of drug release from solid oral dosage forms including 
immediate-sustained release tablets, pellets and capsules (Siwart et al., 2003; Wong 
et al., 2006). 
Dissolution test is used during the development of dosage form for evaluating 
the quality of the tablets or capsules and as an evaluation for comparing new or 
generic formulations with an existing one. More recently, dissolution has become 
important in testing drug release of dosage forms such as powders, chewable tablets, 
, buccal and sublingual tablets, chewing gums, soft gelatin capsules, suppositories, 
transdermal patches, aerosols and semisolids (Siewart et al., 2003). 
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Dissolution provides useful information about the factors that could affect the 
drug release behavior of the controlled release formulations, which include lot to lot 
uniformity, processing variables and stability determination durmg various stages of 
the development process (Siwart et al., 2003). 
It is imperative that in-vitro dissolution test should reflect the conditions in 
gastrointestinal tract. However, this may not always be possible due to the changing 
environment of food status in the gastrointestinal tract. Some of the attributes 
essential for a good in-vitro dissolution system is the reproducible output and 
associated in some way with in-vivo study. The system should be quite sensitive and 
flexible in discriminating between in-vitro variables that may yield differences in-
vivo (Costa and Lobo, 20001). 
The important factors that should be considered in the dissolution tests are 
the types of dissolution apparatus, size and shape of dissolution vessels, volume of 
medium, mixing speed of dissolution medium, temperature and duration of the test. 
However, various dissolution devices have been developed (Banaker, 1991). 
Generally, dissolution systems can be distinguished as the stirred vessel and the open 
flow compartment system (Nelson and Muller, 1979). The official in-vitro 
dissolution methods in the US Pharmacopoeia (1999) for testing oral controlled 
release dosage forms are rotating basket (Wan and Lai, 1991; Ghol and Amin, 1999) 
and paddle methods (Khan et al., 2000; Cerea et al., 2004; Franceschinis et al., 2004). 
The percentage drug dissolved in dissolution media is quantified using 
spectrophotometer or high perfmmance liquid chromatography method (Turkoglu et 
al., 2004). 
23 
The dissolution medium can be buffered at various pH values along the 
gastrointestinal tract. This is helpful to determine the dependence of drug release at 
various sections of gastrointestinal tract. The release kinetics of controlled products 
can be tested with the mathematical models, zero-order, and first-order kinetics, 
Higuchi and cube root of time release. The development of dosage form usually 
begins with in-vitro studies and only when in-vitro dissolution tests have proven 
successful, further evaluation on human or animals can be proceeded (Costa and 
Lobo, 2001; Dokoumetszidis and Macheras, 2006). 
1. 7 Assessment of similarity and dissimilarity factors for drug dissolution 
profiles 
Several methods have · been proposed for the companson of dissolution 
profile. Shah, (1998) proposed multivariate analysis of variance methods to test for 
the difference between two dissolution profiles. Tsang et al. (1996) used multivariate 
distance between two dissolution data sets for dissolution profile comparison. On the 
other hand Chow. (1997) proposed dissolution difference measurement and 
similarity testing based on parameters after fitting a one-degree auto regression time 
series model. Moore and Planner (1996) proposed a simple model-independent 
approach using mathematical indices to define the difference factor (fl) and 
similarity factor (f2) to compare dissolution profiles. This approach has been 
recommended by FDA for comparison of two dissolution profiles. The, similarity 
factor (f2) and different factor (fl) can be calculated by following equation; 
Equation 1.2 
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